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ABSTRACT 
 
Understanding mechanisms viruses use to evade the immune system and to 
persist within its host, is of crucial relevance in controlling, preventing and 
treating HSV-1-associated diseases.   As reviewed in this dissertation, ICP0 is 
a key viral regulatory protein that modulates the switch between lytic and 
latent cycles of the virus.   ICP0’s role in stimulating viral replication is 
mediated, in part, by its impairment of the host defenses.  
 
The purpose of the current study was to undertake structure/function 
analyses of ICP0 that will allow us to begin to delineate how ICP0 promotes 
the dispersion and/or degradation of the antiviral ND10 components and how 
an established IFN response is disarmed by HSV.   From our PML studies, we 
have defined two overlapping regions within the central N-terminal portion of 
ICP0 (residues 1 to 311) that promote the dissociation and degradation of PML 
and dissociation of Sp100 (residues 1 to 427).   Additionally we found that the 
first 388 N-terminal amino acids of ICP0 play a role in impairing the IFN 
response, with the residues spanning from 212-388 being important for this 
activity.   Overall these N-terminal regions of ICP0 play a vital role in impair 
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two host defenses, ND10 and IFN β.   Results from these studies may be used 
to design therapeutic interventions that limit HSV-1 infections and diseases. 
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1. CHAPTER I: INTRODUCTION 
 
Adapted in part from:   “HSV-1 ICP0: An E3 Ubiquitin Ligase That 
Counteracts Host Intrinsic and Innate Immunity”                                
Lanfranca MP, Mostafa HH, Davido DJ. 
Cells. 2014 May 20;3(2):438-54 
 
 
1.1. HERPES SIMPLEX VIRUS TYPE 1 
 
1.1.1.  Significance, Epidemiology, Diseases and Treatments 
 
HSV-1 (herpes simplex virus 1) is a ubiquitous human pathogen that infects 
about 80 % of the world population.   Hallmarks of the infection by HSV-1 are 
its ability to establish a lifelong latent or quiescent infection in the sensory 
neurons, following an initial productive or lytic infection in mucosal or 
epidermal cells [3] (Figure 1-1) and its ability to repeatedly reactivate over time 
[4,5].   A wide range of stimuli, one example being stress, can trigger the switch 
from latent to lytic infection in neurons of the trigeminal ganglia [6].   Upon 
reactivation the virus initiates a productive cycle at the primary site of 
infection, with the potential to spread to nearby epithelial and mucosal cells 
[7].   
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Figure 1-1. Herpes simplex virus latency and reactivation. From the initial 
site of infection in the mucosal surface the virus enters the innervating neurons 
from the trigeminal ganglion and via retrograde microtubule-associated 
transport accesses the neuronal cell body.  DNA persists in the neuronal 
nucleus in a circularized form and expresses the latency associated transcripts 
(LATs). Latency is characterized by the presence of DNA and absence of 
infectious virus.  Different stimuli can induce the reactivation of viral lytic 
infection leading the virion transport back to the primary site of entry resulting 
in a recurrent infection.  ICP0 plays a central role determining whether an 
infection will be productive or latent. (Adapted from Nat Rev Microbiol. 2008 
Mar;6(3):211-21 [1]).  
 
Epithelial Neuronal
Cells Cells
Stress, U.V.
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Herpetic infections range from fever blisters or vesicular eruptions around the 
mouth, called cold sores, to blindness and encephalitis [6].  More than 95 % 
of the ocular infections in adults are due to HSV-1 [8].  Infection of the cornea 
can lead to herpes stromal keratitis (HSK) a potential blinding disease that 
results from recurrent inflammation and corneal scaring [9,10].  
  
Although rare, encephalitis caused by herpes, accounts for 40 to 50 % of the 
total cases of encephalitis [6] and has a mortality rate of almost 70% in 
untreated individuals and leaves severe sequelae in survivors; 90% of herpetic 
encephalitis cases is due to HSV-1, with the remaining 10% caused by HSV-2 
[11].   
 
HSV-1 can also infect the genitals.   Genital lesion are often very painful and 
have been associated with high rates of morbidity and mortality.   HSV-1 has 
been historically associated with oro-facial infections while HSV-2 has been 
more frequently associated with genital herpes.   Nevertheless increases in the 
prevalence of HSV-1 as causative agent of herpetical genital infections has 
been reported in the past years versus HSV-2 [12,13], accompanied by an 
overall decline in the HSV-1 seroprevalence in young populations [14] this 
decline was suggested to be related to increase in genital infection by HSV-1 
resulting from the lack of exposure early in life. 
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HSV poses a severe risk to immunocompromised individuals [15] because of 
its high mortality and morbidity [6] as opposed to self-limiting diseases 
observed in immunocompetent individuals.  In immunocompromised 
individuals HSV can spread to the brain and central nervous system (CNS) 
causing lethal encephalitis [16].   
   
Although rare, vertical neonatal HSV infections occurs from mother to child 
during birth and are often asymptomatic, if left untreated in some neonates it 
can be fatal [17] and those infants that survive severe infections are left with 
significant brain damage [17-19].   
 
Acyclovir (ACV) is the first line of treatment for HSV-1 infections [20,21] and 
acts as a competitive inhibitor of DNA polymerase.  ACV is a guanosine 
analogue that undergoes three phosphorylation steps to become active.    
Initially it is phosphorylated by the viral thymidine kinase (TK) then 
phosphorylated by cellular kinases, and finally recognized by the viral DNA 
polymerase [22],   Notably ACV can only limit lytic infection but does not  
eliminate the virus from an infected cell.  
      
Lengthy antiviral treatment are required to manage immunocompromised 
individuals with a potential issue that such prolonged treatments may 
promote the emergence of new drug-resistant viral strains [20,21,23,24]. 
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Other than ACV, there are no other effective treatments, such as a commercial 
vaccine against HSV-1 to prevent infection or reactivation of latent virus.  
 
 
1.1.2.   Viral Structure and Lytic Replication 
 
 
HSV-1 virion contains a 
lipid bilayer called 
envelope, which is 
embedded with viral 
glycoproteins and serves in 
viral attachment, fusion, 
entry, and spread.   Inside 
the outer envelope is the 
icosahedral nucleocapsid, 
surrounded by an 
amorphous tegument 
comprising of cellular and viral proteins (Figure 1-2).  The viral proteins 
 
Figure 1-2.  HSV structure  
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incorporated in tegument are mainly involved in early events of the viral life 
cycle and counteract host defenses.   The linear ds DNA viral genome is 
contained within the capsid, and is 152 kb in length [6].  
 
The viral genome contains over 80 open reading frames or ORFs.  Although 
the majority of these genes do not have introns, a small subset of viral 
transcripts are spliced.   There is also a group of non-coding RNA that are 
expressed during latency, known as the latency-associated transcripts or LATs 
[5,25].   Overall the genome is composed of two linear fragments of DNA that 
are covalently linked to one another enclosed by short and long inverted 
repeats [6,26].    
 
A hallmark of the herpes-virus family is their temporal cascade of gene 
expression.  Three categories of transcripts and proteins are sequentially 
express: immediate early proteins (IE also designated as α), early (E or β) and 
late (L or γ) proteins (see Figure 1-3).  Their promoter regions differ in their 
degree of complexity.  The IE promoter regions are fairly complex sequences 
and contain specific DNA consensus transcription factor binding motifs 
upstream of the TATA box.   IE genes are activated by binding of three factors: 
cellular Oct1 and HCF and the viral tegument protein VP16 [27].   Five IE 
genes encode the viral proteins: ICP0 (infected cell protein 0), ICP4, ICP22, 
ICP27 and ICP47 [27].   These IE proteins are involved in converging functions 
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that promote the establishment of a lytic infection by counteracting cellular 
antiviral defenses such as viral genome silencing mechanisms and stimulating 
the expression of the E genes [28].   E genes are primarily involved in viral 
genome replication, which stimulates the expression of the L genes.   The L 
proteins function in virion related to assembly and egress or are structural 
components of the virions.  The envelope contains many embedded viral 
glycoproteins and as the viral egresses from the cell it concurrently acquires 
its tegument [6].  
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Figure 1-3.  HSV-1 lytic life cycle. The HSV-1 lytic life cycle starts with 
the fusion of the viral membrane to the cell’s membrane and transport of 
the viral DNA to the nucleus which is rapidly circularizing followed by a 
characteristic temporal cascade of viral gene expression.  Immediate early 
(IE) genes are expressed first, IE proteins stimulate expression of early (E) 
genes. E proteins together with viral DNA replication promote expression of 
the late (L) genes. Finally the viral capsid assembles and is encapsidated 
into virions that egress the cell to complete the infectious cycle.  (Adapted 
from [1] Nat Rev Microbiol. 2008 Mar;6(3):211-21) 
 
ICP0
 
9 
 
 
1.2. ICP0 
 
 
HSV-1 encodes the IE protein ICP0 which functions as an E3 ubiquitin ligase.   
In addition to its E3 ubiquitin ligase activity, ICP0 contains several functional 
domains and activities (see Figure 1-4).   ICP0 is a promiscuous viral 
transactivator of all three classes of HSV-1 genes.   It is important for efficient 
lytic viral replication, especially in low multiplicity of infection conditions and 
has an essential role in regulating the switch between the lytic and latent 
states of HSV-1 [29].   Mutants lacking ICP0 reactivate with reduced efficiency 
in murine models of viral latency and reactivation [30] and expression of ICP0 
 
Figure 1-4.  Functional domains of ICP0.   Schematic of WT ICP0, expressed from WT 
HSV-1.  Selected domains and their amino acid residue boundaries are shown: a RING-
finger motif, a central transactivation domain, a nuclear localization signal (NLS), a C-
terminal transactivation domain (TRANS), which includes an ND10 localization sequence 
(ND10 – loc). Other domains include phosphorylated region I (224-232), SLS-4 (asterisk, 
362-364), phosphorylated region II (365-371), a SIAH-1 binding site (400-410), and a 
USP7 binding site (618-638). 
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by adenoviral vectors has been shown to induce reactivation in primary cell 
culture of latently infected cells [31].  These observations support the 
importance of ICP0 in reactivation. 
  
In addition, ICP0 is known to impair the activation of the type I interferon (IFN) 
response through regulatory factors by affecting the levels or activity of many 
of these proteins amongst which we find IFI16 (IFN γ-inducible protein 16), 
MYD88 (myeloid differentiation factor 88) and Mal (MyD88 adaptor-like 
protein).   
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1.2.1.  ICP0’s E3 Ubiquitin Ligase Activity 
 
 
Ubiquitination is an important regulator of protein function and stability 
within cells [32,33].  This system is regulated by an E1-E2-E3 enzymatic 
cascade that catalyzes the conjugation of ubiquitin (Ub) to target proteins 
while conferring substrate specificity.  Ub monomers are activated by the E1 
enzyme, covalently linked to an E2 (of which, at least 35 E2 enzymes are 
present in humans [34]), and finally transferred from the E2 to the target 
protein in a mechanism facilitated by one of the many hundreds of E3 Ub 
ligases [35].  The first ubiquitination event (mono-ubiquitination) takes place 
between an internal lysine (K) residue within the target protein and a di-  
glycine motif present in the C-terminus of Ub.   As Ub itself contains 7 different 
lysine residues, differing polyubiquitin branch structures can form depending 
on which lysine is the initial conjugated Ub moiety is used, which itself is 
determined by the combined activities of the E2 and E3 enzymes.  This 
conjugation of mono-, multi-, and poly-Ub chains can affect a target protein’s 
function, localization, and/or stability [36].  Typically, K48 linked Ub chains 
marks a protein for proteasomal-dependent degradation [37].   In addition, 
one study showed that Ub was capable of creating linear chains of poly-Ub 
through peptide bond linkage to N-terminal amino groups, which alter the 
functions of target proteins [38]. 
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Figure 1-5. Ubiquitination is the result of three sequential events: ubiquitin-
activation (E1 enzyme), ubiquitin-conjugation (E2s enzymes) and ubiquitin-
protein ligation (E3s enzymes). (Adapted form [15] Metzger et al. J Cell Sci 125: 
531-537; 2012). 
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ICP0 has the ability to synthesize or direct chains of poly-Ub in vitro and in 
cell culture on cellular targets, including PML [39-46]; Sp100 [39,40,46,47], 
CENP-A, -B, -C [48-51], DNA-PKcs [47,52,53], RNF-8 and RNF-168 [53], CD83 
[54], USP7[55,56], IκBα [57], p53 [58], IFI16 [59,60] and E2FBP1 [61], as well 
as certain SUMOylated targets  [62].   Degradation of these targets allows HSV-
1 to evade the host’s intrinsic and innate responses, thereby facilitating viral 
replication [63].   In addition to proteasome-mediated degradation, the E3 Ub 
ligase activity of ICP0 was recently suggested to be linked to mechanisms that 
counteract the host defenses through proteasome independent processes [64], 
providing ICP0 yet with an additional strategy to counteract cellular antiviral 
defenses.   Overall, the Ub ligase activity of ICP0 plays a central role in HSV-
1 replication by impairing components of the hosts’ intrinsic and innate 
antiviral responses.   Intrinsic defenses are cellular factors that are always 
present and ready to repress viral transcription or infections [65].    Another 
branch of the antiviral resistance is the innate immunity, where particular 
molecules or patterns associated with viral replication activate a gene cascade 
to finally express effector proteins [66].   This activation in host gene 
expression leads for example to the synthesis of type I IFNs, which present a 
major defense mechanism against viruses [73-75]. 
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 1.2.2. Impairment of the Interferon Response  
 
 
IFN proteins [67,68] are a family of cytokines, which share the ability of 
inducing interference of viral infections [69].  This group of cytokines is 
constituted by three different major components: type I, type II and type III 
IFNs.   Within the type I IFN, encoded by intron-less genes in humans, there 
are 5 different types –α (composed of 13 subtypes) –β, -ε, - κ, and –ω (2) 
interferons [70].   There is only one subtype of IFN II ( also known as IFN γ) 
which is mainly synthesized in specialized cells from the immune system 
such as natural killer (NK) and T lymphocytes [71].   Finally there are 3 
classes of type III IFNs (also known as IL28/29): IFN-λ1, IFN-λ2 and IFN-λ3 
[72,73].  Of these families of IFN proteins, two members of the type 1 family 
(α, β) have been shown to be synthesized shortly after viral attachment or 
penetration and the type 1 IFN response has been was shown to be essential 
in limiting viral infection [74-76].   Consequently the focused of our studies 
on type 1 IFNs will be centered in the impairment of the interferon response 
upon IFN β pretreatment or activation.   All the interferon types or classes 
differ in their mechanisms of activation and their receptors on the cell surface 
and cytosol.   Almost all nucleated cells are capable of producing and 
responding to type I IFN in reaction to viral infection, which is critical for the 
cells’ antiviral resistance to HSV-1.  
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Viral genomes are the common feature or pattern that is recognized triggering 
the antiviral response.  There are two different systems that independently 
promote IFN induction: a ubiquitous cytosolic sensor mediated by RIG-I 
(retinoic acid inducible gene I), MDA5 (melanoma differentiation antigen 5) 
and TLRs (toll like receptors) which are typically expressed in specialized 
surveillance cells such as macrophages and dendritic cells [77]. 
 
Although both cellular cytosolic sensors and TLRs can independently activate 
type I IFNs in vivo, they are not redundant in their functionality [66]. 
    
IFNs exert their effect through the expression of several hundreds of IFN 
stimulated genes (ISGs) that mediate various biological responses within the 
host.  Some ISGs are regulated by both IFN I and II, while the others are 
distinctly regulated by a singular type of IFN.   Many target genes are part of 
the intrinsic immunity other induce apoptosis and another group influences 
or activates components in adaptive immunity, making IFNs key regulatory 
mediators of the immune response.   Ultimately, the stimulation of multiple 
IFN-induced genes by type I IFNs establishes an antiviral state and promotes  
immunomodulatory functions the host.  Not surprisingly, the products of 
ISGs are often targets of viruses for the purpose of immune-evasion to ensure 
propagation of progeny virions [70]. 
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The involvement of ICP0 in the impairment of an established IFN response 
was observed when ICP0 null mutant viruses were shown to be very sensitive 
to the effects of IFN-β or -α in cell culture and in a mouse model of HSV-1 
latency [78,79].  The mechanism(s) by which ICP0 impairs the type 1 IFN 
response of the host are largely unknown.  The purpose of the current study 
was to undertake structure/function analyses of ICP0 to identify specific 
domains required for this activity of ICP0, allowing us to ultimately delineate 
how the type 1 IFN response is disarmed by HSV through ICP0-cellular 
protein interactions.    
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Figure 1-6. JAK–STAT pathways activation by type I and type II IFNs. All type I 
IFNs bind a common receptor at the surface of human cells. The type I IFN receptor 
(subunits, IFNAR1 and IFNAR2, associated with the Janus activated kinases (JAKs) 
tyrosine kinase 2 (TYK2) and JAK1, respectively). The type II IFN, IFN-γ, binds the type 
II IFN receptor (subunits:IFNGR1 and IFNGR2, associated with JAK1 and JAK2, 
respectively). Activation of the JAKs results in tyrosine phosphorylation of STAT2 and 
STAT1; this leads to the formation of STAT1–STAT2–IRF9 complexes (ISGF3) which 
translocate to the nucleus and bind IFN-stimulated response elements (ISREs) in DNA 
to initiate gene transcription. Both type I and type II IFNs also induce STAT1–STAT1 
homodimers that translocate and bind GAS (IFN-γ-activated site) elements present in 
the promoter of certain ISGs, thereby initiating the transcription of these genes. 
Adapted from J Biol Chem. 2007 Jan 19;282(3):1757-68 [2] 
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1.2.3.   ICP0 Disruption of ND10  
 
 
Nuclear domain 10 (ND10) are protein complexes localized inside the nucleus 
of the cell.   This organelle is involved in several cellular processes including 
DNA damage, apoptosis, senescence, IFN response, and protein degradation 
[80-83].  This dynamic structure 
is comprised of multiple cellular 
proteins (Figure 1-7) that are 
activated by HSV-1 [84] and other 
DNA- and RNA-containing 
viruses [81].  Subsequent to viral 
infection, ND10-associated 
proteins are recruited to incoming 
viral genomes implying a 
potential repressive function for 
some or all the components of 
this organelle, given that  upon 
activation many of its 
constituents have shown the 
ability to limit the replication of an ICP0 null HSV-1 mutant [85-87].   Among 
 
 
Figure 1-7. ND10 bodies are multi-
protein complexes, these sub-nuclear 
structures that have been associated with 
several cellular functions among which we 
find the interferon response and antiviral 
defenses. 
PML
Sp100
Daxx
PML
Sp100
DaxxPML
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the repressive components we find: the main component and organizer of 
ND10s, PML (promyelocytic leukemia) and other constitutive members Sp100 
(speckled protein of 100 kDa), hDaxx (human death domain-associated 
protein 6), and ATRX (alpha thalassemia/mental retardation syndrome X-
linked) proteins, among others.   Through its E3 Ub ligase activity ICP0 can 
promote the disruption of ND10s by mediating either directly or indirectly the 
protein degradation of many ND10 components including: PML and Sp100 
[39-41,46,88-91]. ICP0 in addition promotes the dissociation of hDaxx and 
ATRX [43].   By disrupting ND10s ICP0 appears to stimulate viral transcription 
by counteracting the repression of ND10 components.     ICP0 has a preference 
to degrade small ubiquitin-like modifier (SUMO) tagged PML and Sp100 
proteins [44] and reduces the overall prevalence of SUMO-tagged proteins 
placing ICP0 as a STUbL [44] not surprisingly, ICP0 contains the several 
SUMO-interacting motifs (SIMs) possesses (Figure 1-4).  The depletion of 
various ND10 components partially complements the replication of an ICP0 
null mutant, and such complementation is further enhanced if the proteins 
are concomitantly depleted [92].  
  
A link between PML, Sp100, SUMO, and innate defenses has been suggested 
as PML and Sp100 are ISGs (reviewed in [39]), with type 1 IFNs being an 
important part of the innate immune response. Furthermore, SUMOylation of 
PML and Sp100 increases in IFN-treated cells and correlates with an increase 
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in the size and number of ND10s [93,94].  Overall, ND10s and other 
SUMOylated proteins perform to recruit cellular antiviral repressors [95], 
making ND10s and SUMO important players in the intrinsic response against 
HSV-1, which is ultimately inactivated by ICP0’s E3 Ub ligase activity. 
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1.3. OVERALL SUMMARY AND HYPOTHESIS 
 
 
 
Understanding mechanisms viruses use to evade the immune system and to 
persist within the host, is of crucial relevance in controlling, preventing and 
treating all the HSV-1 associated diseases.   As reviewed in this dissertation 
ICP0 is a key viral regulatory protein that modulates the switch between lytic 
and latent cycles of the virus.   ICP0’s role in stimulating viral replication is 
mediated, in part, by its impairment of the host defenses.  
 
Structure/function analyses of ICP0 described in this dissertation will enable 
us to begin to understand how HSV-1 ICP0 promotes the dispersion and 
degradation of ND10 components (Chapter 2) and dismantles the IFN 
response (Chapter 3).   The observations from these studies can be applied to 
design therapeutic interventions to limit HSV-1 infections and diseases. 
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2. CHAPTER 2: TWO OVERLAPPING REGIONS WITHIN THE 
N-TERMINAL HALF OF ICP0 FACILITATE THE 
DEGRADATION AND DISSOCIATION OF PML AND 
DISSOCIATION OF Sp100 FROM ND10 
 
 
Adapted from: “Two overlapping regions within the N-terminal half of 
the HSV-1 E3 ubiquitin ligase ICP0 facilitates the degradation and 
dissociation of PML and dissociation of Sp100 from ND10” 
Mirna Perusina Lanfranca, Heba H. Mostafa and David J. Davido 
         J Virol. 2013 Dec;87(24):13287-96 
 
 
2.1.   ABSTRACT 
 
 
Herpes simplex virus type 1 (HSV-1) establishes a lifelong latent infection in 
sensory neurons and can reactivate from latency under stress conditions.  To 
promote lytic infection, the virus must interact with specific cellular factors to 
evade the host’s antiviral defenses.  The HSV-1 E3 ubiquitin ligase, infected 
cell protein 0 (ICP0) activates transcription of viral genes, in part, by mediating 
the degradation of certain cellular proteins that play a role in host antiviral 
mechanisms.  One component of the cellular defenses that ICP0 disrupts is 
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the sub-organelle, nuclear domain (ND) 10, by inducing the degradation and 
dissociation of the major organizer of ND10, promyelocytic leukemia (PML) and 
ND10 constituent, Sp100.   Because previously identified domains in ICP0 
only partially explain how it directs the degradation and dissociation of PML 
and Sp100, we hypothesized that additional regions within ICP0 may 
contribute to these activities, which in turn facilitate efficient viral replication.  
To test this hypothesis, we used a series of ICP0 truncation mutants and 
examined PML protein levels and PML and Sp100 immunofluorescence 
staining in human embryonic lung cells.  Our results demonstrate that two 
overlapping regions within the central N-terminal portion of ICP0 (residues 
212 to 311) promoted the dissociation and degradation of PML and 
dissociation of Sp100 (residues 212 to 427).   In conclusion we have identified 
two additional regions in ICP0 involved in altering ND10 antiviral defenses in 
a cell culture model of HSV-1 infection.   
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2.2.   INTRODUCTION 
 
 
HSV-1 is an alpha-herpes-virus that establishes latency in humans.  
Infections of individuals with HSV-1 can cause cold sores, potentially blinding 
ocular infections, and life-threatening encephalitis.  The virus has a 
characteristic temporal cascade of gene expression ordered into three classes: 
immediate-early (IE), early (E), and late (L).  ICP0 (infected cell protein 0) is 
one of the five IE proteins that facilitates viral gene expression and impairs 
the host’s antiviral responses to infection.   Although not an essential protein, 
ICP0 plays a key role in the establishment of lytic infection and reactivation 
from latency [96-98].   ICP0 is a RING-finger containing E3 ubiquitin ligase 
[99].   E3 Ub ligases direct the attachment of ubiquitin molecules to target 
proteins, regulating their function or marking them for degradation by the 
proteasome.   The ubiquitin-proteasome system has been characterized as a 
major component for cellular protein degradation, whose biological functions 
extend to the regulation of basic cellular processes [32,100-102].   Through its 
E3 ligase function, ICP0 transactivates viral gene expression from all three 
kinetic classes and impairs cellular intrinsic [65,103] and innate antiviral 
responses [78,104,105], which include chromatinization of the viral genome 
[106-108], inactivation of the DNA damage response [53,103,109], and the 
induction and establishment of the type 1 interferon response [104,105,110].   
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As previously mentioned, ICP0 has an important role during viral infection by 
counteracting host antiviral defenses.   In addition to impairing the interferon 
response, ICP0 interferes with intrinsic defenses, which act to immediately 
suppress one or more steps in the HSV-1 life cycle [80,81,85,86].   A key 
component of the host’s intrinsic resistance to viruses is PML (promyelocytic 
leukemia) nuclear bodies, also known as nuclear domain 10 (ND10) [111-113].  
This dynamic subnuclear complex contains a variety of proteins that are 
recruited to these nuclear domains by PML, a major constituent of ND10 
[81,114].  Other components of ND10 include the cellular proteins Sp100, 
hDaxx, and ATRX [43,81,113].   ND10 is associated with cellular processes 
that include DNA damage, protein degradation, apoptosis, senescence, and 
interferon signaling [80-83]. 
  
It has been hypothesized that ND10 and its constituent proteins repress 
transcription of the virus by enveloping viral genomes and limiting their 
interactions with host factors that stimulate viral transcription [44,92].  
Consequently, the activation of viral gene expression by ICP0 is linked to its 
ability to disrupt ND10 by directing the dissociation and/or degradation of 
ND10 constituents such as PML and Sp100 and their SUMO-modified forms 
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Figure 2-1. Functional domains of ICP0 and ICP0 truncation mutants. 
A) Schematic of WT ICP0, expressed from WT HSV-1, and mutant forms of 
ICP0 expressed from the viruses n720, n680, n525, n428 and n212 are 
shown above; each ICP0 mutants contain a nonsense linker insertion within 
the ICP0 gene [12]. Selected domains and their amino acid residue 
boundaries are shown: a RING-finger motif, a central transactivation 
domain, a nuclear localization signal (NLS), a C-terminal transactivation 
domain (TRANS), which includes an ND10 localization sequence (ND10 – loc). 
Other domains include phosphorylated region I (224-232), SLS-4 (asterisk, 
362-364), phosphorylated region II (365-371), a SIAH-1 binding site (400-
410), and a USP7 binding site (618-638). B) Schematic of additional mutant 
forms of ICP0 generated as previously described [12, 10].  
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[39,43].   Further support that ND10 components play important roles in the 
function of ICP0 and the HSV-1 life cycle comes from key observations that an 
ICP0 null mutant can be partially complemented by cells depleted of PML, 
Sp100, hDaxx, or ATRX [43,85,86,92,115], with a further these enhancement 
in viral replication when cells are depleted for two or more of  proteins [85,92].  
   
To date, only three domains or motifs in ICP0 have been identified that mediate 
the disruption of ND10 via the dissociation and/or degradation of PML, Sp100, 
hDaxx, and/or ATRX.   Specifically, the RING-finger motif (Fig. 1), which 
directs the E3 ubiquitin ligase activity of ICP0, is required for the dissociation 
of ND10 components [116].   In addition, a portion of the C-terminus (amino 
acids 633-767, Fig. 1) of ICP0 contains an ND10 localization domain 
[117,118]; this domain and the nuclear localization signal (NLS, Fig.1) of ICP0 
facilitate its dissociation and degradation of PML and Sp100 and ND10-
disrupting activities [46,118,119].  Recently, Cuchet-Lourenҫo, et al. have 
reported interactions between an N-terminal region of ICP0 (amino acids 1 to 
388) with a single PML isoform (I) in two yeast hybrid assays [45], suggesting 
one potential mechanism by which ICP0 directs the degradation and/or 
dissociation of PML.  Because all of these domains in ICP0 provide only a 
partial explanation as to how ICP0 alters PML and Sp100 levels, we 
hypothesized that additional regions within ICP0 likely contribute to PML 
and/or Sp100 dissociation/degradation, which in turn facilitates efficient viral 
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replication.   Consequently, we performed structure-function analyses using 
a series of ICP0 truncation mutants (Figure 2-1) and examined PML levels by 
flow cytometry and western blots and the subcellular localization of PML, 
Sp100, and ICP0 by immunofluorescence.   From our results, we conclude 
that the first 311 N-terminal amino acids of ICP0 mediate the dissociation and 
degradation of PML and the first 427 amino acids the dissociation of Sp100; 
residues from 212-311 and 212-427 within this N-terminal-half of ICP0 are 
required for both set of these activities, respectively. 
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2.3. MATERIALS AND METHODS 
 
2.3.1.   Cells and Viruses 
 
HEL-299 (human embryonic lung) cells and Vero (African green 
monkey kidney) cells were maintained at 37°C in 5% CO2, and 
cultured in either alpha minimum essential medium (αMEM) and 
Dulbecco’s modified Eagle medium (DMEM) for Vero cells 
supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), 
and 2 mM L-glutamine and 10 or 5 % fetal bovine serum (FBS), 
respectively.  Human embryonic derived cell lines, WI-38+PML-GFP 
cells and L7 cells (Vero cells stably transformed with the ICP0 gene) 
were grown and maintained as previously described [120,121].  Wild 
type (Wt) HSV-1 (strain KOS), 7134 (an ICP0 null mutant), and ICP0 
truncation mutants (n212, n428, n525, n680, and n720) were 
propagated as previously described [96,98].  Titers for the ICP0 
mutant viruses were determined on L7 cells. 
pAlter-1+ICP0 was used to create the ICP0 truncation mutants, n312 
and n389, by inserting a nonsense Spel linker while removing a 
specific restriction site (either NruI or NotI) with the pAlter site-
mutagenesis kit following the manufacturer’s instructions.  
Introduction of the mutations into the plasmid was confirmed by 
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DNA sequencing.  Mutant viruses were generated by co-transfection 
of the respective mutation containing plasmid and 7134 genomic 
DNA at a ratio of 3:1 µg into Vero cells plated in 60 mm dishes at 
3x105 cells per plate.  Selection of mutant viruses was performed 
using white/blue selection in the presence of X-gal (5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside) and Phenol Red for at least 
three subsequent rounds, and confirmed by Southern blot analysis. 
 
2.3.2.  Flow Cytometry 
 
WI-38+PML-GFP cells or WI38-GFP cells were plated at 5x105 cells 
per well in 6-well plates.  24 h later, the cells were infected at an MOI 
of 5, 10, or 20 (as noted in Figure 2), with KOS or one of the ICP0 
mutant viruses for 1 h at 37°C.  WI-38+PML-GFP cells express the 
first 539 N-terminal amino acids of PML fused with GFP.  Infected 
cells were washed 3 times with phosphate-buffered saline (PBS) to 
remove unabsorbed viruses and placed back into growth medium.  
For each time point, cells were washed three times with PBS, 
trypsinized, resuspended twice in 0.5% bovine serum albumin 
(BSA)/PBS, and fixed with 4% paraformaldehyde in 0.5% BSA/PBS.  
Fluorescence levels were monitored in a Beckman Flow Cytometer 
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(BD, Biosciences) collecting at least 20,000 events per sample.  
Results were analyzed using CellQuest software (BD, Biosciences). 
 
2.3.3.  Western Blots 
 
HEL-299 cells were plated at 5x105 in 6-well plates.  24 h later, the 
cells were infected at an MOI of 5 with KOS or ICP0 mutant viruses.  
At 6 or 9 h post infection (hpi), the cells were washed 3 times with 
PBS prior to being scraped into boiling 1X Laemmli buffer containing 
protease inhibitors (1 µg/mL aprotinin, 1 µg/mL leupeptin, 1 mM 
phenylmethylsulfonyl fluoride), vortexed, and heated for additional 5 
min at 95ºC.  7.5% of each sample was resolved and using 4-12% 
Bis-Tris gradient gel (Invitrogen) and subsequently transferred to 
nitrocellulose membranes.  Membranes were blocked for 1 h at room 
temperature with 2% nonfat dry milk in Tris-buffered saline with 
0.05% Tween 20 (TBS-T). Blots were probed for ICP0 overnight at 4ºC 
(H11060, Santa Cruz Biotechnology) in blocking buffer.  After three 
washes with TBS-T, membranes were probed with goat-anti-mouse 
IgG-horseradish peroxidase (HRP) (Jackson ImmunoResearch).  After 
an additional three washes with TBS-T, the membranes were 
developed using ECL reagents (SuperSignal West Femto 
Chemiluminescent Substrate, ThermoFisher Scientific).  The 
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membranes were then washed with TBS-T prior to stripping them for 
30 min at 50ºC in 100 mM 2-mercaptoethanol, 62.5 mM, (Tris pH 
6.7), 2% SDS.  Blots were again blocked as before prior to being 
probed overnight for PML (A301-167A, Bethyl Laboratories) and β-
actin ((I-19)-R, Santa Cruz Biotechnology), both diluted in blocking 
buffer.  After washing, the membrane was incubated with goat-anti-
rabbit IgG-HRP (Jackson ImmunoResearch) and developed as before.  
All images were assembled using Adobe Photoshop and Adobe 
Illustrator. 
 
2.3.4.  Immunofluorescence  
  
HEL cells or WI-38+PML-GFP were plated 24 h prior to infection at 
50% confluence on rat collagen-coated coverslips.  Cells were 
infected at an MOI of 5 with KOS or each mutant virus as above in 
αMEM.  At specific time points, the coverslips were washed with PBS 
and fixed and permeabilized as previously described [122] Coverslips 
were labeled with primary antibody incubated for 1 h a tissue culture 
incubator at 37ºC, washed three times with PBS, labeled with 
secondary antibody in the same manner as primary antibody, 
washed three times with PBS, and then mounted onto slides using 
ProLong antifade (Invitrogen).  Primary antibodies used were: ICP0 
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(H11060 or rabbit polyclonal IgG PAC 3678, Pacific Immunology); 
PML (A301-167A, Bethyl Laboratories or sc-5621, Santa Cruz 
Biotechnology); Sp100 (sc-16328, Santa Cruz Biotechnology); 
Secondary antibodies: goat anti-mouse IgG2b Dylight 488 (Jackson 
ImmunoResearch); goat anti rabbit IgG Rhodamine Red-X (Jackson 
ImmunoResearch); donkey anti-rabbit IgG Dylight 594 (Jackson 
ImmunoResearch); cow anti-goat IgG Dylight 488 (Jackson 
ImmunoResearch).  All antibodies were diluted in 0.5% FBS and 
0.5% BSA/PBS.  Slides were examined using a Nikon Eclipse TE-
2000 U fluorescence microscope and photographed using with a 
CoolSNAP EZ digital camera (Photometrics) with NSI Elements 
Software (Nikon).  Images were assembled in Adobe Photoshop and 
Adobe Illustrator.  At least 100 cells that expressed ICP0 were 
examined for PML or Sp100 staining to quantify the extent Wt or 
each mutant form of ICP0 altered the staining of either cellular 
protein.  Cells were categorized as either staining positive or negative 
for PML or Sp100.   Criteria for negative staining included cells that 
lacked antigen expression, had half or less the intensity of staining, 
or had half or less the number of punctae relative to the negative 
controls (mock- and 7134-infected cells).  In addition, we observed a 
minor degree of HSV Fc receptor staining, and took this staining 
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profile into account when we examined PML localization in HSV-1-
infected cells.  
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2.4. RESULTS 
 
2.4.1.  ICP0 Mutants Mediate the Dissociation and Degradation 
of Exogenous PML  
 
 
 The viral IE protein, ICP0, has been shown to promote the degradation of the 
antiviral protein, PML [46,88,123].   To better understand how ICP0 induces 
the dissociation and degradation of PML from ND10, our approach was to 
identify new region(s) within ICP0, other than its RING finger and in its C-
terminus that play a role in these functions.  For these studies, we used a 
series of viruses in which nonsense linkers have been inserted into the ICP0 
gene, giving rise to forms of ICP0 progressively truncated at its C-terminus 
(Figure 2-1A) [96]. 
 
To initially monitor the dissociation of PML, we examined exogenous PML-GFP 
fluorescence in a human embryonic cell line (PML-GFP-WI38 cells) by 
fluorescent microscopy at 3, 6 (Figure 2-2) and 12 hpi.  After initial 
observations established the existence of a differential gradient ability for each 
ICP0 truncation mutants and the Wt virus, KOS, showing capable to promote 
loss of fluorescent signal from PML-GFP within the cells, we decided to use a 
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more precise method to quantify and compare the loss of PML-GFP promoted 
by each virus using flow cytometry, a method that has successfully being used 
by our lab to monitor ICP0’s E3 ubiquitin ligase activity [120].  To examine 
and quantify the loss of PML-GFP fluorescence induced by KOS and each ICP0 
mutant virus, cells were mock infected or infected with KOS or each ICP0 
mutant, and the fluorescence signal of each sample was examined at 6 and 
12 hpi (Figures 2-2A and B) [124,125].  In Figure 2-3A, histograms for mock 
and virally infected cells at 6 hpi were vertically aligned.  The ‘y’ vertical line 
intersects the peak for the PML-GFP mock-infected sample.  The ‘x’ vertical 
line intersects the KOS and n720 peaks at 6 hpi, which showed a reduction in 
fluorescence compared to mock-infected cells.  n680, n525, and n428 had 
curves with PML-GFP levels that fell between mock- and KOS-infected 
samples.  n212- and 7134-infected samples had curves with fluorescence 
intensities nearly identical to mock-infected cells.  
  
When we quantified the levels of PML-GFP fluorescence in cells, we noted that 
there were three statistically distinguishable groups.  KOS and n720 were very 
efficient at inducing the loss of PML-GFP with 12-20% levels compared to 
mock-infected cells, which were given a value of 100%.  The next group of 
mutant viruses that were significantly different from KOS- and mock-infected 
cells was n680, n525, and n428.  Reduced levels of PML-GFP (45-62%) were 
observed for n428, n525, and n680, although these reductions were not as 
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large as those resulting from infection by n720 or KOS (Figure 2-3B).   The 
mutant form of ICP0 encoded by n212 was the only truncation mutant unable 
to significantly decrease PML-GFP fluorescence (~90% levels) for both time 
points, which were comparable to mock- and 7134-infected cells. (Figure 2-
3B).  Furthermore, even when PML-GFP-expressing cells were infected with 
n212 at higher MOIs (10-20) for up to 12 h, PML-GFP signals were still largely 
unaffected (Figure 2-3C), suggesting that the defect in this form of ICP0 was 
not due to slower kinetics of PML-GFP dissociation or degradation but an 
inability of this the mutant to promote the efficient dissociation of PML. 
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Figure 2-2. Loss of PML-GFP fluorescence by KOS and ICP0 truncation 
mutants by microscopy.  PML-GFP-expressing cells were mock infected or 
infected at an MOI of 5 with KOS or each ICP0 truncation mutant viruses.  At 6 
hpi, cells were fixed and visualized by fluorescence microscopy at 400X 
magnification. 
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Figure 2-3.  Loss of PML-GFP fluorescence by K0S and truncation mutants 
by flow cytometry. PML-GFP-expressing cells were mock infected or infected 
at an MOI of 5 with KOS or each ICP0 mutant viruses. At 6 or 12 hpi, the cells 
were trypsinized, fixed and analyzed by flow cytometry.   A) Representative 
histograms taken from cells at 6 hpi. 20,000 events were analyzed for each 
histogram   B) The MFI (mean fluorescence intensity) of each sample was used 
to calculate the relative fluorescence compared to the mock-infected cells 
(assigned the value of 100%).                                       [Continued on next page] 
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Overall, these data show that the first 427 amino acids of ICP0 help facilitate 
the dissociation (and degradation) of PML-GFP from ND10 and that residues 
from 212 and 427 in this portion of ICP0 are required for these activities.  
Additionally, our results indicate that residues from 679 to 719 are necessary 
for ICP0 to efficiently promote the loss of PML-GFP.  These data are in 
agreement with a previous study indicating a role for this region in the 
targeting of ICP0 to ND10s, facilitating the dissociation of PML from ND10 and 
PML’s degradation [46].  
   
6 hpi, n≥13 independent experiments; 12 hpi, n≥5 independent experiments. Data 
were analyzed using one-way ANOVA, Tukey’s b multiple comparison post-test. 
Asterisks indicate significant differences (p≤0.05) relative to mock-infected cells. C) 
PML-GFP-expressing cells were mock infected or infected at an MOI of 5, 10, or 20 
with KOS or ICP0 mutant viruses, n212 or 7134.  The MFI of each sample was used 
to calculate the relative fluorescence compared to the mock-infected cells (assigned 
the value of 100%). 12 hpi, n≥2 independent experiments for each MOI.  Data were 
analyzed using one-way ANOVA, Tukey’s b multiple comparison post-test. Asterisks 
indicate significant differences (p≤0.05) relative to mock-infected cells. 
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2.4.2.   A region of ICP0 Spanning Residues 212-427 Is Critical for the 
Degradation of Endogenous PML  
 
 
Figure 2-4. KOS and ICP0 truncation mutants induce the degradation of 
endogenous PML protein levels. Virally-infected or mock-infected HEL cells 
were harvested and lysed at 6 hpi.  A) PML and B) ICP0 protein levels were 
examined by western blots.  β-actin levels were included as loading controls.  A 
representative set of images from 5 independent experiments is shown. 
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Because we examined the effects ICP0 truncations mutants have on 
exogenously expressed PML, we next wanted to determine whether these 
mutants affected endogenous PML in a comparable manner.  Consequently, we 
analyzed endogenous PML protein levels at 6 hpi in HEL cells (Figure 2-4).  The 
results were generally consistent with those obtained by flow cytometry of PML-
GFP (Figure 2-3A and B).  Again, there was a link between the size of each 
mutant form of ICP0 and its ability to promote the degradation of PML.  7134- 
and n212-infected cells had PML levels similar to that of mock-infected cells.  
n428 mutant form of ICP0 was capable of reducing PML protein levels, 
although not to same extent as the larger truncated forms of ICP0.  This 
experiment indicated that the first 427 amino acids of ICP0 assist in the 
degradation of PML by 6 hpi, with the region spanning residues 212 to 427 
critical for this function.  Furthermore, residues from 428 to 524 are required 
for the efficient degradation in these assays.  
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2.4.3.   Subcellular Localization of ICP0 Truncations Mutants   
We then infected cells with KOS or each ICP0 truncation mutant for 3, 6, and 
9 hpi to monitor the subcellular localization of ICP0.  For Wt ICP0 expressed 
from KOS, our results matched those of a previous report [126] in which ICP0 
localization changes over time from being primarily nuclear during the initial 
stages of infection (e.g., 3 hpi) to a mix of nuclear and cytoplasmic ICP0 
between 3 and 6 hpi, and finally localizing predominantly to the cytoplasm at 
6 hpi and later (Figure 2-5).  When we examined the subcellular localization 
of the ICP0 truncation mutants, the mutant forms of ICP0 expressed from 
n525, n680 and n720 were predominantly nuclear at 6 and 9 hpi (Figure 2-5).  
These mutant forms possess a nuclear localization signal (NLS) (Figure 1A), 
and they did not localize extensively to the cytoplasm later during viral 
infection as observed for Wt ICP0.  The n212 and n428 mutant form of ICP0 
was found in both the nucleus and cytoplasm at 6 and 9 hpi (Figure 5).  
Interestingly, ICP0 expressed from n212 and n428 lacks ICP0’s NLS, but both 
proteins were able to diffuse into the nucleus during infection; this localization 
is likely associated with their apparent molecular weights (i.e., ~35 kDa and 
~58 kDa, Figure 8A), as proteins that are ≤60 kDa have been reported to be 
capable of diffusing through the nuclear pore [127].   The former two mutants, 
n212 and n428 were notably enriched in the nucleus in some cells at later 
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times during infection; this enrichment could be facilitated by their 
interaction(s) with a one or more ND10 constituents or ISG proteins.   
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Figure 2-5. ICP0 localization in cells infected with KOS and ICP0 truncation 
mutants.  HEL cells were infected (MOI 5) with KOS or each ICP0 truncation 
mutant or mock infected for 3, 6 and 9 h.  Cells were fixed, permeabilized, and 
immunostained for ICP0 and visualized by fluorescence microscopy at 400X 
magnification. 
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2.4.4.   Two N-terminal Regions of ICP0 Are Necessary for ICP0 to 
Dissociate PML and Sp100 from ND10   
To determine how these truncated mutant forms of ICP0 affected PML 
localization over time, we performed immunofluorescence assays in HEL cells.  
Initially, cells were infected with KOS or each ICP0 truncation mutant for 3, 6 
and 9 hpi to monitor the subcellular localization of ICP0 (Figure 2-6) were a 
time lapse of infection is depicted with accompanying schematic 
representation following the localization of PML and ICP0 as the infection 
progresses. As the infection evolves we observe PML dissociation form ND10 
structures, with initial colocalization with ICP0 and further on during infection 
ICP0 dispersion to the cytoplasm was observed. 
We then examined PML and ICP0 staining in virally-infected cells at 6 hpi 
because this time point resulted in >90% loss of PML staining with Wt ICP0.  
the staining ICP0 mutants n720 and n680 appeared to be similar to KOS in 
directing the dissociation of PML (Figure 2-7A), as ≤2% of cells that expressed 
Wt ICP0 or the n720 mutant form or the n680 mutant form of ICP0 stained 
positive for PML (Figure 2-7B).  Limited loss of PML staining was detected in 
n525- and n428-infected cells, with 8-32% of cells that expressed ICP0 positive 
for PML (Figure 2-7A and B).  In the case of n212 at 6 hpi, the majority (61%)  
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of cells that expressed this truncated form of ICP0 stained positive for PML 
(Figure2-7A and B).  Notably, this mutant form of ICP0 partially colocalized 
with PML by 9 hpi (Figure 2-8)  PML staining of 7134-infected was comparable 
to mock-infected cells (Figure 2-7A).  To exclude the possibility that the n212 
mutant was capable of dissociating PML in a delayed manner, infections with 
n212 were allowed to continue for 12-24 hpi; even at these later time points, 
the n212 truncation was unable to promote the further loss of PML staining.  
Thus, all truncation mutants were capable of promoting different degrees of 
PML dispersal from ND10 structures over time.  Comparable results for PML 
staining for all of the truncation mutants were observed with two other PML 
antibodies (M. Perusina Lanfranca and D. J. Davido, unpublished data), 
demonstrating the relative specificity and reproducibility of PML staining by 
the Wt and mutant forms of ICP0 in this assay.  
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Figure 2-6. Schematic representation of PML dispersion from ND10s upon 
infection with Wt HSV-1. Diagram of ICP0 and PML staining with a respective 
immunofluorescent image shown underneath each cell.  HEL cells were infected 
with an MOI of 5 up to 9 hpi.  Cells were fix, permeabilized and stained, labelling 
PML in red and ICP0 in green. Arrows denote cells expressing ICP0.   Co-
localization between ICP0 and PML is indicated by yellow fluorescence. Cells were 
visualized by fluorescence microscopy at 400X magnification and images 
processed using Adobe Photoshop software. 
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Figure 2-7.  KOS and ICP0 truncation mutants mediate the loss of 
endogenous PML staining.  A) HEL cells were infected at an MOI of 5 with 
KOS, each ICP0 truncation mutant, or 7134, or were mock infected.  At 6 
hpi cells were fixed, permeabilized, and immunostained with antibodies that 
recognize ICP0 and PML.  ICP0 is labeled in green, and PML is labeled in red 
in the Merge.  Arrows indicate an infected cell. B) Graph representing the 
percentage of ICP0-expressing cells that stained positive (+) and negative (-) 
for PML by immunofluorescence. For each mutant (except of 7134) at least 
100 ICP0-expressing cells were analyzed with ImageJ software.  
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Sp100 has been shown to stabilize ND10 by protecting PML from ICP0-
mediated degradation, while promoting the repression of HSV-1 IE expression 
[87].  Because the ICP0 mutants showed a spectrum of PML dissociation 
phenotypes, we then asked how these mutant forms of ICP0 affected the 
staining of the Sp100.  Infections were carried out as described in the PML 
immunofluorescence experiments, and ICP0 and Sp100 staining was 
monitored at 6 hpi. (Figure 2-9A).  As previously reported, Wt ICP0 expressed 
 
 
Figure 2-8. The truncation mutant n212 induces partial dissociation of 
PML from ND10s by 9 hpi. HEL cells were infected at an MOI of 5 with 
KOS, each ICP0 truncation mutant, or 7134, or were mock infected.  At 9 
hpi cells were fixed, permeabilized, and immunostained with antibodies that 
recognize ICP0 (green) and PML (red) and colocalization as yellow in the third 
column.   
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from KOS efficiently dispersed Sp100 from ND10 by 6 hpi (Fig. 2-9A and B) 
[39,42].  The staining profiles of Sp100 for the ICP0 truncation mutant viruses 
were similar to the results obtained with PML.  n720 and n680 mutant forms 
of ICP0 were ≤12% positive for Sp100 staining, which were in a comparable 
range to Wt ICP0 expressed by KOS (Fig. 2-9A and B).  There was a gradual 
increase in Sp100 staining for n525 and n428, where 23% and 29% of the 
n525- and n428-expressing cells, respectively, were Sp100 positive (Fig. 2-9A 
and B).  Most cells (77%) that expressed n212 mutant form of ICP0 contained 
Sp100 at 6 hpi (Fig. 2-9A and B).  7134- and mock-infected cells maintained 
punctate Sp100 staining (Fig. 2-9A).  To confirm our results with Sp100 
staining, we tried to examine Sp100 protein levels by western blot analysis 
using the same primary antibody from our Sp100 immunofluorescence 
experiments.  Unfortunately, this antibody was not functional in western blot 
assays.  
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Figure 2-9.  KOS and ICP0 truncation mutants direct the loss of 
endogenous Sp100 staining.  A) HEL cells were infected at an MOI of 
5 with KOS, each ICP0 truncation mutant, or 7134 or were mock 
infected for 6 h.  Cells were subsequently fixed, permeabilized, and 
immunostained with antibodies that recognize ICP0 and Sp100. ICP0 is 
labeled in red, and Sp100 is labeled in green in the Merge.  Arrows 
indicate an infected cell. B) Graph representing the percentage of ICP0-
expressing cells that stained positive (+) and negative (-) for Sp100 by 
immunofluorescence. For each mutant (except of 7134) at least 100 
ICP0-expressing cells were analyzed with ImageJ software. 
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2.4.5.    An 100 Amino Acid N-terminal Region of ICP0 Is Key for 
the Degradation and Dissociation of PML from ND10 
 
 
To define the sub-region from amino acids 212 to 428 of ICP0 that is 
necessary for directing the dissociation and degradation of PML we generated 
two new truncation mutants, n312 and n389, which express the first 311 and 
388 amino acids of ICP0, respectively (Figures 2-1B and 2-10A).  Using these 
and other ICP0 mutants (e.g., n428, n212, and 7134), we examined 
endogenous PML levels by western blot in HSV-1-infected or from ND10 in 
HSV-1- or mock-infected HEL cells at 9 hpi.   We chose to examine PML levels 
at 9 hpi to determine whether these mutant forms of ICP0 would be capable 
of directing the degradation of PML, if given additional time.   As shown in 
Fig. 2-10A, all ICP0 linker insertion mutants we tested were capable of 
mediating the loss of PML, with the exception of n212 by 9 hpi.  Notably, 
n312, n389, and n428 significantly directed the degradation of PML. In the 
case of n428, there appeared to be a greater degree of PML degradation at 9 
hpi compared to 6 hpi (Fig. 2-4A). Thus, we have defined the region from 
amino acids 212 and 311 of ICP0 involved in the degradation of PML by 9 hpi.   
Using these ICP0 mutants, we examined the dissociation of PML and Sp100 
cells that expressed the n428, n389, and n312 mutant forms of ICP0 stained 
positive for PML, whereas >65% of the n212-expressing cells were positive for 
 
56 
 
PML staining (Figure 2-10B and C).  These data largely mirrored our results 
for the PML western blots shown in Figure 2-10A.  When Sp100 
immunofluorescence was examined, there was a clear boundary between 
n428 and the other truncation mutants (Figure 2-10D and E).  Specifically, 
22% of the cells that expressed the n428 mutant form of ICP0 stained positive 
for Sp100, whereas 55-77% of n389-, n312-, and n212-expressing cell were 
positive for Sp100 (Figure 2-10E).    Furthermore, our immunofluorescence 
experiments with n389 and n312 indicate that these viral mutants are not as 
efficient in dissociating Sp100 from ND10 compared to PML. 
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Figure 2-10.  Truncation mutants n312 and n389 induce the degradation 
of endogenous PML protein levels and alter endogenous PML and Sp100 
staining.  A) Infected or mock-infected HEL cells were harvested and lysed at 9 
hpi.  PML and ICP0 protein levels were examined by western blots.  β-actin levels 
were included as loading controls.  A representative set of images from 4 
independent experiments is shown. B) - E) HEL cells were infected at an MOI of 
5 with KOS, ICP0 truncation mutants n212, n312, n389, n428, or 7134 or were 
mock infected for 6 h.  Cells were subsequently fixed, permeabilized, and 
immunostained with antibodies that recognize ICP0 and either B) PML or D) 
Sp100. Arrows indicate an infected cell. Graph representing the percentages of 
ICP0-expressing cells that stained positive (+) and negative (-) for C) PML or E) 
Sp100 by immunofluorescence were determined for each mutant (except of 
7134) by examining at least 100 ICP0-expressing cells using ImageJ software. 
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our immunofluorescenceexperimentswithn389andn312indicate that these 
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viral mutants are not as efficient in dissociating Sp100 from ND10 compared 
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Figure 2-10.  Truncation mutants n312 and n389 induce the 
degradation of endogenous PML protein levels and alter endogenous 
PML and Sp100 staining.  A) Infected or mock-infected HEL cells were 
harvested and lysed at 9 hpi.  A) PML and ICP0 protein levels were examined 
by western blots.  β-actin levels were included as loading controls.  A 
representative set of images from 4 independent experiments is shown. B) - 
E) HEL cells were infected at an MOI of 5 with KOS, ICP0 truncation mutants 
n212, n312, n389, n428, or 7134 or were mock infected for 6 h.  Cells were 
subsequently fixed, permeabilized, and immunostained with antibodies that 
recognize ICP0 and either B) PML or D) Sp100. Arrows indicate an infected 
cell. Graph representing the percentages of ICP0-expressing cells that 
stained positive (+) and negative (-) for C) PML or E) Sp100 by 
immunofluorescence were determined for each mutant (except of 7134) by 
examining at least 100 ICP0-expressing cells using ImageJ software. 
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Summarizing our results for PML and Sp100 from Figs.2-4 through 2-10 in 
Table 2-1, the first 311 amino acids assists in mediating the dissociation and 
degradation of PML, whereas the first 427 amino acids of ICP0 direct the 
dissociation of Sp100 from ND10. Thus, residues from 212-311 are critical 
ICP0’s PML dispersal and degradation activities, given that the truncated n212 
form of ICP0 was unable to promote the degradation of PML and efficiently 
alter the staining of PML. Amino acids 212 to 427 are involved in the dispersal 
of Sp100 from ND10.  Lastly, the C-terminal half of ICP0 (amino acids 428-
720) facilitates the efficient dissociation of PML and Sp100.  
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Table 2-1. ND10 disruption and plating efficiency  
virus 
PML Sp100 plating 
efficiency b Dissoc./loss degradation Dissoc./loss 
6h 6h 9h 6h  
 
KOS 
 
nearly 
complete 
complete 
 
complete 
 
nearly 
complete 
1.2 
n720 
nearly 
complete 
nearly 
complete 
complete a 
nearly 
complete 
13 
 
n680 
 
nearly 
complete 
nearly 
complete 
complete a 
nearly 
complete 
6.5 
n525 
nearly 
complete 
nearly 
complete 
complete partial 4.5 
n428 Partial partial 
nearly 
complete 
partial 12 
n389 Complete partial a 
nearly 
complete 
limited 48 
n312 Partial partial a 
nearly 
complete 
very limited 79 
n212 very limited 
not 
evident 
not evident very limited 114 
7134 not evident 
not 
evident 
not evident not evident 310 
 
a: unpublished data.   
b: The efficiency of plating for each virus is the ratio of viral titers on L7 versus Vero cells.  
Values are derived from 2-4 independent experiments. 
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2.5. DISCUSSION 
 
 
ICP0 is a multifunctional protein, and many of its functions have been linked 
to its E3 ubiquitin ligase activity, which requires its RING-finger domain [128].  
The E3 ubiquitin ligase activity of ICP0 has been associated with the 
proteasomal dependent degradation of several cellular proteins, including PML 
[39-46]; Sp100 [39,40,46,47], CENP-A, -B, -C [48-51], DNA-PKcs [47,52,53], 
RNF-8 and RNF-168 [53], CD83 [54], USP7[55,56], IκBα [57], p53 [58], IFI16 
[59,60] and E2FBP1 [61], as well as certain SUMOylated targets  [62].  
Degradation of these targets allows HSV-1 to evade the host’s intrinsic and 
innate responses, thereby facilitating viral replication.   
 
In the current study, we sought to understand how ICP0 mediates the 
dissociation of PML and Sp100, degradation of PML, and disruption of ND10, 
as PML, Sp100, and ND10 play important roles in intrinsic and innate 
immunity [65,103].  While the RING-finger motif, NLS, and particular regions 
of the C-terminus of ICP0 have been shown to facilitate the dissociation and 
degradation of PML and Sp100 and the degradation of PML [46,123], we 
hypothesized that other regions or domains in ICP0 are required to impair 
PML and Sp100 function.  This hypothesis was tested in structure-function 
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analyses using a series of progressively shorter ICP0 truncation mutants 
(Figure 2-1).  We observed that there was a gradation in the ability of the 
mutants to mediate the dissociation of exogenous PML-GFP, the degradation 
of endogenous PML, and the dissociation of endogenous PML and Sp100 from 
ND10.  Specifically, our studies show that the smallest truncation mutant, 
n212, had no or limited effects on PML-GFP, PML, and Sp100 staining and did 
not affect PML levels (Figures 2-3 through 2-10) by 6 or 9 hpi.  This mutant 
form of ICP0 has been reported to possess E3 ubiquitin ligase activity in vitro 
[122].  Thus, our data indicate that the first 211 amino acids of ICP0 are 
partially capable of dispersing PML but do not mediate its degradation, 
suggesting that these two activities of ICP0 are not entirely coupled to each 
another.  In contrast, n428 moderately affected PML-GFP, PML, and Sp100 
staining and PML levels.  The remaining viral mutants, n525, n680, and n720 
were similar as or more efficient in these activities of ICP0 than n428, which 
does not contain the NLS of ICP0 (Fig. 2-1A).  Thus, it is possible that the 
predominant nuclear localization of the n525-n720 mutant forms of ICP0 
facilitates its ND10-disrupting activities (Fig. 2-5).  Notably, the PML and 
Sp100 staining profiles and PML levels of these ICP0 mutants largely correlate 
with their respective transactivation, complementation, and replication 
phenotypes (Table 2-1 and [96,98]).  With the addition of the ICP0 mutants, 
n312 and n389, we were able to be better define the boundaries of ICP0 that 
result in the loss of PML protein levels and PML and Sp100 staining.  Overall, 
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our data indicate there is a minimal region of ICP0 (amino acids 1-311) that 
directs the dispersal and degradation of PML, which lies within the minimal 
region (amino acids 1-427) of ICP0 that dissociates Sp100 from ND10; the 
residues from 212-311 and 212-427 are required for their respective 
functions. 
     
In addition to the ICP0 structure-function analyses highlighting the 
importance of other motifs/regions in ICP0 (i.e., RING-finger, NLS, and C-
terminus) in facilitating the dissociation and degradation of ND10 
components, a recent study by Cuchet-Lourenҫo, et al indicated that ICP0 can 
interact with a particular isoform of PML (i.e., PML I) in co-
immunoprecipitation assays [45].  These same investigators established by 
yeast-two hybrid assays that the N-terminal 388 amino acids of ICP0 interact 
with PML, and the residues from 242 to 388 are necessary for this interaction.  
The domain required for PML dissociation and degradation (amino acids 212-
311) maps to this region of ICP0, suggesting that residues from 241-311 of 
ICP0’s N-terminus participate in the binding of at least one isoform of PML to 
mediate the ubiquitination, degradation, and dissociation of PML from ND10.  
Also, our ICP0-Sp100 data indicate that an additional region in ICP0 (residues 
212-427) is required for the dissociation of Sp100, implying that ICP0 
regulates the dispersal of Sp100 by other or additional mechanisms from those 
required for PML.   
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As previously mentioned, our mapping studies identified residues from amino 
acids 212-311 as very relevant in playing a role for the dissociation and 
degradation of PML and 212-427 for the dissociation of Sp100.  In addition to 
the aforementioned PML interaction domain, functional motifs within the 
larger of the two domain (212-427) of HSV-1 ICP0 (see Fig. 2-1A) include the 
two phosphorylated regions (Region I: 224-232 and Region II: 365-371 
[129,130]), a SUMO-interacting motif (SIM) (SLS-4, residues 362-364 [44]), 
and a binding site for the E3 ubiquitin ligase, SIAH-1 (residues 401-410 [131]).  
Of these motifs, only phosphorylated Region I lies within the required PML 
dissociation/degradation domain of ICP0 (residues 212-311).  Mutation of 
phosphorylated Regions I and II of ICP0 in the absence of other viral factors 
diminished the E3 ubiquitin ligase and/or altered the ND10-disrupting 
activities of ICP0 [130]. Furthermore, viral mutants containing these 
mutations (i.e., Phos 1 and Phos 2) were impaired for viral replication in cell 
culture and/or mice [130,132].  Mutation of the ICP0 SIM, SLS-4, diminished 
the complementation and reactivation capabilities of ICP0, especially when 
this mutation was expressed in truncated forms of ICP0 (residues 1-396 and 
1-594) [44]. In the case of SIAH-1, its depletion increased the stability of ICP0, 
and an ICP0 SIAH-1 binding site mutant in HSV-2 had a modest decrease in 
viral replication [131].  For the PML- and Sp100-associated activities of ICP0, 
we speculate that these motifs likely serve collective or redundant roles and 
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thus their individual contributions are only apparent when expressed in the 
N-terminal fragment of ICP0.  Future experiments will address this possibility.    
Furthermore, while we have discovered that there is a minimal region of ICP0 
that mediates these activities, our results also suggest that other 
regions/domains from amino acids 428 to 775 facilitate PML and Sp100 
dispersal, PML degradation, and ND10 disruption.  We propose that these 
additional domains in the C-terminus, besides the NLS, stabilize the binding 
of ICP0 to its target proteins, including PML, for ubiquitination.  It is known 
that ICP0 can preferentially target SUMO-conjugated proteins such as PML 
and Sp100 for proteasomal degradation [44].  Furthermore, ICP0 contains 
several known SIMs, which appear to be redundant in function [44].  Thus, 
SUMO-SIM interactions are linked to ICP0 functions as PML and Sp100 are 
modified by SUMO, and PML, Sp100, and other ND10 constituents contain 
SIMs that are necessary for their recruitment to sites to incoming HSV-1 
genomes [44,45,92,95].  Ultimately, all of these interactions contribute to 
ICP0’s multi-faceted role in impairing the host’s intrinsic antiviral response.  
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3.  CHAPTER 3: THE HSV-1 E3 UBIQUITIN LIGASE ICP0 
REGION FROM AMINO ACIDS 1 TO 388 IS INVOLVED IN 
THE IMPAIRMENT OF THE HOST’S INTERFERON 
RESPONSE 
 
 
    
3.1. ABSTRACT 
 
Herpes simplex virus type I (HSV-1) is a human pathogen capable of 
establishing lifelong latent infections in the host and can reactivate from 
latency under stress.   The ability of the virus to persist in its host comes from 
a series of activities the virus possesses to disarm distinct the immune 
defenses.   The HSV-1 E3 Ub ligase ICP0 is a multifunctional protein that is 
able to promote the degradation of several cellular factors and transactivate 
all kinetic classes of viral genes and allows HSV-1 to replicate in the face of 
the host’s interferon (IFN) response.   Notably, ICP0 null mutant viruses have 
been shown to be very sensitive to the effects of an established type I IFN (e.g. 
IFN-α or –β) response in cell culture and in a mouse model of HSV-1 infection.  
Little is known about the overall mechanism(s) by which ICP0 allows HSV-1 
to replicate when the type 1 IFN response has been activated.   Consequently 
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the purpose of the current study was to identify domains in ICP0 that allow 
HSV-1 to be largely resistant to the antiviral effects of IFN-β.   
 To identify one or more domains, we used a series of ICP0 truncation mutants 
and performing plaque reduction, viral yields, and gene expression assays in 
the absence and presence of cells pretreated with IFN-β.   We determine that 
the first 388 N-terminal amino acids of ICP0 play a role in conferring 
significant resistance of HSV-1 to IFN β, with residues  from 212-311 
mediating this resistance.   We conclude that we have identified a minimal 
region in the N-terminus of ICP0 that contributes to the resistance of HSV-1 
to an established IFN β response.  
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3.2.  INTRODUCTION 
 
 
Herpes simplex type 1 (HSV-1) is a ubiquitous pathogen that infects between 
60 to 80% of the human population worldwide.   Herpetic infections range 
from fever blisters or vesicular eruptions around the mouth and genitals to 
blindness and encephalitis [6,12,13].   HSV-1 infection is a severe risk for 
immunocompromised individuals [6,15], because the virus can spread to the 
brain and central nervous system (CNS), causing lethal encephalitis [16]. 
 
A hallmark of HSV-1 infections is the ability of the virus to infect and 
establishing a lifelong latent infection the sensory neurons of its hosts’ 
trigeminal ganglia [133].   Latency is characterized by the absence of infectious 
virus while the viral genome persists in the neurons.   Under conditions of 
stress HSV-1 can reactivate from latency leading to the production of progeny 
virus [6].   During productive infection, HSV-1 initiates a temporal gene 
expression of immediate early (IE), early (E), and late (L) genes.   Among the 
IE proteins infected cell protein 0 (ICP0) is required for efficient lytic viral 
replication by stimulating all classes of viral genes [124] and regulates the 
switch between the lytic and latent stages of infection ICP0’s E3 ubiquitin 
ligase activity promotes the ubiquitination and degradation of several cellular 
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components of the host defenses [63].   One function that ICP0 confers to HSV 
is resistance to antiviral factors known as type 1 IFNs.  
 
IFNs [67,68] are a family of cytokines, capable of interfering with viral 
infections in the host [69], in part, by inducing an innate response [66].   There 
are three classes of IFNs in humans, in which two members of the type 1 
family (i.e., α, β) are synthesized shortly after viral attachment or penetration 
and promote an innate immune response [74-76].   These IFNs are secreted 
and activate the JAK-STAT signal transduction cascade, stimulating the 
expression of hundreds of ISGs and a subset of proteins encoded by these 
genes are known to affect viral mRNA stability and processing and translation 
of viral mRNAs [65].   Additionally, IFNs can also stimulate the adaptive 
immune response of the host providing yet another mechanism by which type 
I IFNs limit viral replication. 
    
Many viruses have developed countermeasures against IFNs allowing for viral 
persistence and transmission [70].   In the case of HSV-1, ICP0 plays an 
important role in resistance to IFN response.   ICP0’s role in modulating a 
pre-existing type I IFN response comes from several studies demonstrating 
that ICP0 null mutants are highly sensitive to the effects of type 1 IFNs, IFN-
α or –β in cell culture and in a mouse model of HSV-1 infection [78,79,134].  
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This deficiency in viral growth for an ICP0 null mutant can be complemented 
by the expression of exogenous Wt ICP0 [134]. 
 
The mechanism(s) by which ICP0 impairs a pre-existing IFN response of the 
host are largely unknown.   To begin to address potential mechanisms, we 
performed structure-function analyses of ICP0 to define one or more domains 
required for this activity, providing possible insights into how ICP0 aids HSV-
1 in disarming the inhibitory effects of IFN-β.   Using replication assays in cell 
culture, we identified that the first 388 N-terminal amino acids of ICP0 are 
involved in impairing the IFN-β response, with residues from 212-388 within 
this N-terminal-half of ICP0 required for this impairment.   Potential 
implications from our study are discussed. 
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Figure 3-1. Functional domains of ICP0 and ICP0 truncation mutants. 
A) Schematic of WT ICP0, expressed from WT HSV-1, and mutant forms of 
ICP0 expressed from the viruses n720, n680, n525, n428 and n212 are 
shown above; each ICP0 mutants contain a nonsense linker insertion within 
the ICP0 gene [12]. Selected domains and their amino acid residue 
boundaries are shown: a RING-finger motif, a central transactivation 
domain, a nuclear localization signal (NLS), a C-terminal transactivation 
domain (TRANS), which includes an ND10 localization sequence (ND10 – loc). 
Other domains include phosphorylated region I (224-232), PML degradation 
domain (212-312), SLS-4 (asterisk, 362-364), phosphorylated region II (365-
371), a SIAH-1 binding site (400-410), and a USP7 binding site (618-638). B) 
Schematic of additional mutant forms of ICP0 generated as previously 
described [12, 10].  
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3. 3.   MATERIALS AND METHODS 
 
3.3.1. Cells and Viruses.   
HEL-299 (human embryonic lung) cells, HepaRG cells (human 
hepatocyte cell line) and its derivatives and, Vero (African green 
monkey kidney) cells and its derivatives were maintained at 37°C in 
5% CO2. HEL-299 cells were cultured in alpha minimum essential 
medium (αMEM) containing 10% fetal bovine serum supplemented 
with penicillin (100 U/ml), streptomycin (100 µg/ml), and 2 mM L-
glutamine.  Vero cells were cultured in Dulbecco’s modified Eagle 
medium (DMEM) for Vero cells containing 5% fetal bovine serum 
supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), 
and 2 mM L-glutamine.   HepaRG [135] and HepaRG-shPML [92] 
cells were maintained in William’s E media containing 10% FBS, 2 
mM L-glutamine, 10 U/mL penicillin, 0.5 µM hydrocortisone, and 5 
µg/mL insulin. L7 cells (Vero cells stably transformed with the ICP0 
gene) were grown and maintained as previously described [136].   
Wild type (Wt) HSV-1 (strain KOS), 7134 (an ICP0 null mutant), and 
ICP0 truncation mutants (n212, n312, n389, n428, n525, n680, and 
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n720) were propagated as previously described [96,124,137].  Viral 
titers for KOS were determined on Vero cells and for all ICP0 mutant 
viruses were determined on L7 cells. 
 
 
3.3.2. Plaque Reduction Assays.  
HEL-299, Hepa-RG, Hepa-RG shPML, Vero, or L7 cells were plated 
in 24-well plates at 1x105cells/well. The next day cells were 
untreated or treated with 1000 U/ml of human IFN-β (AbD Serotec) 
in their respective medium.  After 15 h of IFN-treatment, cells were 
infected with 10-fold serial dilutions of the respective Wt HSV-1 and 
ICP0 mutant viruses. After a 1 h incubation at 37°C, cells were 
overlaid with cell culture medium containing 0.5% methylcellulose 
with or without IFN-β (1000 U/ml). After 3 days post infection, 
cultures were washed with PBS and fixed with 3.7% formaldehyde, 
probed 1 h, at RT (room temperature) with rabbit anti-HSV-1 
polyclonal antibody and another hour with a horseradish peroxidase 
conjugated anti-rabbit (Jackson Immunoresearch).  Plaques were 
visualized with Vector Red substrate (Vector Labs). Stained plates 
were scanned with a scanner (Cannon), and plaque numbers and 
image processing were done using Image J (Rasband, W.S., ImageJ, 
U. S. National Institutes of Health, Bethesda, Maryland, USA, 
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http://imagej.nih.gov/ij/, 1997-2014) and Adobe Photoshop 
software.   Ratio was calculated as the titer of the viral stock (PFU/ml) 
in the absence of IFN-β over the titer of each viral stock in the 
presence of IFN-β.  
 
3.3.3. Viral Growth Yield Assays.   
Hepa-RG cells were plated in 12-well plates at 1x105cells/well, and 
the next day cells were either mock-treated or not with 1000 U/ml of 
human IFN-β.   15 h prior to infection.  Cells were infected with HSV-
1 or ICP0 mutants at an MOI of 1 for 1h, and acid wash treated 
treated to inactivate unabsorbed viruses, adding back medium in the 
absence or presence of 1000 U/ml of human IFN-β.  After 24 h of 
infection, samples were harvested and frozen at -80oC.  The titer of 
each viral sample was determined on Vero (KOS) or L7 (ICP0 
truncation and deletion mutants) cells, respectively.  Statistical 
analysis was done using Paired t test (p≤ 0.05).  
 
  
3.3.4. RT qPCR 
HEL-299, HepaRG and HepaRGshPML cells were plated at 1 x 105 
cells per well. Next day cells were treated or not treated with human 
IFN-β at 1000 U/mL.  After three PBS washes cells were harvested 
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in Trizol (Invitrogen), and cDNA synthesized with iScript cDNA 
synthesis kit (Bio-Rad).  For each sample, real time PCR was 
performed using FastStart SYBR green master (Rox) (Roche) in a 
StepOnePlus Real-Time PCR System (Applied Biosystems).  
Transcripts were amplified using the following primer sets: 
 hTBP (5’-TGCACAGGAGCCAAGAGTGAA-3’and5’ 
CACATCACAGCTCCCCACCA-3’), 
 ISG15 (5’-GGTGGACAAATGCGACGAAC-3’ and 5’-
ATGCTGGTGGAGGCCCTTAG-3’) and  
PML (5’- AGGAAGTGCAGCCAGACCCAGTG-3’ and 5’- 
TGAGACTGCCTTGGAGGTGCTGG-3’).   
 hTBP levels were used to normalize other transcript levels.   
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3.4. RESULTS 
 
 
3.4.1.  A Region Between Amino Acids 212 and 427 within the N-
terminus of ICP0 Is Involved in the Impairment of the IFN Response 
 
 
As previously mentioned, ICP0 is crucial for the ability of HSV-1 to overcome 
a pre-induced type 1 IFN response.  Using the ICP0 truncation mutants in 
mentioned in the previous chapter along with Wt HSV-1 and an ICP0 null 
mutant (7134), we performed plaque reduction assays in 3 cell types in the 
absence and presence of IFN-β.  Of the cell types examined, we used Vero 
(African green monkey kidney) cells, which are responsive to IFN treatment 
but unable to synthesize it [138].   Additionally, we chose a primary cell strain, 
human embryonic lung (HEL) 299 cells, for these experiments, as HEL cells 
are capable of responding to and synthesizing type 1 IFNs induced by viral 
infection [126,139].  Lastly, a Vero complementing cell line (L7 cells), which 
contains the ICP0 gene, was included in this study to confirm that alterations 
in ICP0 gene were responsible for the plaquing phenotypes we observed with 
our ICP0 mutants. 
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When we evaluated the plaque reduction assay results performed in the 
presence IFN-β, in all three cell lines, we noticed that there was a reduction in 
plaque size for all viruses tested compared to the absence of IFN-β, with the 
exception of 7134 and n212, which will be discussed later.  These results 
indicate that IFN-β impacts the HSV-1’s ability to spread from cell-to-cell, 
whether ICP0 or a mutant form of the protein is expressed by the virus. 
 
We then compared the plaquing efficiencies of each virus on the 3 cell lines by 
taking the ratio of viral titers in the absence of IFN-β versus in the presence of 
IFN-β.   Consequently, the higher the ratio the more difficult it is for a virus to 
plaque on IFN-β-treated cells. For 7134 and n212, plaques could not be 
detected with these viruses upon the addition of IFN-β.   In this instance, the 
lowest dilution of virus tested was given the value of 1 to estimate the level of 
its impairment.  
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Figure 3-2. Wt HSV-1, ICP0 null, and ICP0 C-terminal truncation mutants in 
plaque reduction assays with the presence and absence of IFN-.  HEL, Vero 
and L7 cells were plated in 24-well plates, treated or not with 1000 U/ml of 
human IFN- in their respective medium.  After 15 hours of IFN-treatment, cells 
were infected with 10-fold serial dilutions of the respective ICP0 Wt (KOS), null 
(7134) and C-terminus truncation mutant viruses. 3 dpi cells were fixed and 
stained by Immunohistochemistry with a polyclonal antibody anti-HSV-1. A) 
Titers were determined as PFU/ml in -/+ IFN for KOS, 7134 and C-terminal 
truncation mutants. Asterisks indicate that plaques were not identified for these 
viruses at the lowest dilution tested with IFN-β and were given the value of 1 for 
estimating this ratio.  B) Images of infected wells showing immunohistochemically 
stained plaques of each virus are shown for all three cell types in the -/+ IFN-.  
n: 4 – 14 for A) and B). 
 
82 
 
When we examined the plaquing of Wt HSV-1 and ICP0 mutants in HEL and 
Vero cells, we were unable to detect plaques in the presence of IFN-β for 7134 
and the smallest ICP0 truncation mutant, n212 [125,140].   Previous reports 
have indicated that ICP0 n212 is a null mutant.   However, we were able to 
detect the expression of this protein during infection (Figures 2-5, 2-10 and 
[91]), this mutant form of ICP0 appears to possess some E3 Ub ligase activity 
in vitro [122], and it can colocalize and disperse PML from ND10, albeit in a 
limited manner [91].   Based on these results, we do not consider n212 to be 
a true ICP0 null mutant.  Nevertheless, these experiments showed that n212 
is as severely compromised as ICP0 null mutant in IFN-β-treated HEL and 
Vero cells (Figure 3-2 and 3-3).   The rest of the truncation mutants exhibited 
a decrease in their sensitivity to IFN-β that approximately correlated with their 
size (summarized in Table 3-1).   In the two cell types, the ratio for n428 ranged 
from 20-80 fold relative to KOS (Wt HSV-1).   Reductions in n525, n680, and 
n720 ranged from 10-60 fold compared to KOS.  All truncation mutants were 
capable of plaquing in the presence of IFN-β with the exception of n212, 
suggesting that the region between amino acids 212 and 427 of ICP0 plays a 
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role in diminishing IFN-β’s repressive effects on viral replication.   These  
 
 
Figure 3-3. Plaque reduction assay with KOS, 7134 and ICP0 truncation 
mutants in HEL cells. HEL cells were plated in 24-well plates, treat or not with 
1000 U/ml of human IFN-β in the respective media.  After 15 hours of IFN-
treatment, cells were infected with 10-fold serial dilutions as indicated, of the 
respective ICP0 Wt (KOS), and ICP0 null (7134) and truncation mutant viruses. 
3 dpi cells were fixed and stained by Immunohistochemistry with a polyclonal 
antibody HSV-1. Viral plaques are shown in red. 
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defects in plaquing induced by IFN-β were overcome in L7 cells, indicating the 
effects we observed for all ICP0 mutants tested could be complemented by Wt 
ICP0 (Fig. 3-2A and B).   
  
Once we defined the region from residues 212 to 427 of ICP0 as facilitating 
HSV-1 replication when induced with IFN-, we sought to better map region(s) 
in this portion of ICP0 responsible for this phenotype.   As a result, two 
additional mutant viruses with stop codon linker insertions were generated as 
previously described [91] and included in our plaque reduction assay.   These 
mutants, n312 and n389 (Figure 3-1), were tested under the same conditions 
in HEL cells with the majority of viruses used in our previous experiments 
(Fig. 3-2).   An example of a plaque reduction assays with these viruses is 
shown in Figure 3-3.  
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Table 3-1.  Wt HSV-1 and Truncation Mutants’ Relative Sensitivity to IFN-β 
 
 
Viruses Sensitivity to IFN-β 
7134, n212 &  n312 +++++ 
n389 ++++ 
n428 +++ 
n525, n680 & n720 ++ 
KOS + 
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Figure 3-4. Plaque reduction assay in HEL with KOS, 7134 and 
ICP0 truncation including n312 and n389.   HEL cells were infected 
and treated as in Fig. 3-4 with 1000 U/ml of human IFN-β.   Ratio 
calculated corresponds to n≥4 experiments, with error bars 
representing the standard errors of the means. Asterisks indicate that 
plaques were not identified for these viruses at the lowest dilution 
tested with IFN-β and were given the value of 1 for estimating this 
ratio. 
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For these experiments, n312 was as sensitive as n212 and the ICP0 null 
mutant to IFN-β, such that we were essentially unable to detect plaques.  n389 
was impaired for plaquing upon the addition of IFN-β to basically the same 
extent as n428.   From this new set of experiments we would classify n312 as 
being very sensitive to IFN group and n389 as being only moderately sensitive.   
With this data, we have defined the region from residues 1-388 of ICP0 as 
important for HSV-1 to impair a pre-induced IFN-β state.  
 
 
3.4.2. ICP0 Viral Growth Yields in the Presence of INF-β Indicate 
that the Region Spanning from Residues 1 to 388 Is Responsible for 
ICP0’s Impairment of the Interferon Response  
 
 
To determine if the phenotypes observed in our IFN-β plaque reduction assays 
correlated with reductions in viral replication, we performed viral growth 
assays in the absence and presence of IFN-β.  Using the same viruses as in 
the plaque reduction assay, HEL or HepaRG cells were infected at an MOI of 
1.  We included HepaRG cells in these experiments as there is a high 
requirement for ICP0 on HSV-1 replication in these cells, and they are 
responsive to IFN-β [135].  When compared side by side, both HEL and HepaRG 
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cells respond to exogenous IFN-β by stimulating the expression of two typical 
ISGs, ISG-15 and -56 (Figure 3-5).     
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Figure 3-5. ISG15 and ISG56 induction upon IFN-β treatment in HEL and 
HepaRG cells. HEL cells or HepaRG cells were treated with 1000 U/ml of human 
IFN-β for the indicated time.  At 0 and 24 h post treatment, total RNA was isolated 
from cells and reversed transcribed into cDNA for qRT-PCR analysis to monitor 
ISG15 and ISG56 transcript levels upon IFN-β induction.  n= 2 experiments. 
1
10
100
0h 24h 24h +
R
e
la
ti
v
e
 t
ra
n
s
c
ri
p
t 
le
v
e
ls
 o
f 
IS
G
1
5
HepaRG
HEL
1
10
100
0h 24h 24h +
R
e
la
ti
v
e
 t
ra
n
s
c
ri
p
t 
le
v
e
ls
 o
f 
IS
G
5
6 HepaRG
HEL
 
90 
 
 
 
 
 
 Ratio 83 ≥9273 ≥12809 354 114 123 21 61 ≥32513 
 
Figure 3-6. Viral Yields of KOS, 7134 and ICP0 truncation mutants in HepaRG 
cells in the presence and absence of IFN-β.   HepaRG cells were pretreated or not 
with IFN-β (1000 U/mL) and were infected 15 post-treatment with KOS, 7134 or 
ICP0 truncation mutants at 1 PFU/cell.  Samples were harvested 24 hpi and titered 
by plaque assays.  n≥ 4 experiments. Error bars represent the standard errors of 
the means. 
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When we used both cell types in viral growth assays, HEL cells were 
unfortunately very sensitive to acid washes, which we include in this 
experiments to inactivate extracellular virus.   Given this difficulty, we 
performed our yield assays in HepaRG cells (Figure 3-6).  
  
Results obtained in these assays correlated well with the plaque reduction 
assays in Figures 3-2, 3-3, and 3-5, distinguishing the viral replication 
phenotypes of n312 and n389.   For this set of experiments the inhibition of 
viral growth with IFN- for KOS and n720 and showed similar reductions, with 
n680 being slightly less sensitive to IFN-than KOS.  Reductions for n525 and 
n428 were only ~1.5-fold lower with compared to KOS (Figure 3-6).  Lastly, the 
plaquing of n389 was at least reduced 4.3-fold with respect to KOS, whereas 
decrease in n312 plaquing was 154-fold.  We were unable to detect viral 
replication for n212 and 7134 in the presence of IFN-for approximately half 
of the experiments we performed.   These data indicate the first 388 N-terminal 
amino acids of ICP0 expressed by HSV-1 are sufficient to allow for appreciable 
viral replication when the type 1 IFN response has been activated in HepaRG 
cells.    
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3.4.3.    PML Depletion Marginally Increased the Plaquing 
Efficiency of ICP0 Truncation Mutants in the Presence of INF-β 
As previously mentioned in Chapter 2 [91], we identified a domain in ICP0 
known ability to promote PML degradation and dissociation of PML and Sp100 
from ND10 structures.  Given our initial studies showed that overlapping 
regions impair the IFN response and affected the dispersal of PML (an ISG), 
we wanted to examine PML’s contribution in the IFN response as it related to 
our ICP0 structure-function studies.   It was previously shown that depletion 
of one or two specific PML isotypes only modestly complemented the 
replication phenotype of an ICP0 null mutant [92,115]. 
  
We then asked the questions, does depletion of PML alleviate IFN--mediated 
restriction on n212 compared to other ICP0 truncation mutants?   To answer 
that question we obtained HepaRG cells and HepaRGshPML cells, which are 
depleted for PML.   After confirming by RT PCR that PML transcript levels were 
reduced in HepaRGshPML cells (Mirna Perusina Lanfranca and David Davido 
unpublished data), we performed a set of IFN- plaque reduction assays in 
HepaRGshPML cells and parental HepaRG cells using Wt HSV-1, an ICP0 null 
mutant, and the majority of our ICP0 truncation mutants (Figure 3-7).   In the 
absence of IFN pretreatment, there was no apparent complementation in the 
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HepaRGshPML cells (Fig. 3-8).   We then performed plaque reduction assays 
in the mock- or pre-treated IFN- cultures.    
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Figure 3-7. Plaquing with KOS, 7134 and ICP0 truncation mutants in 
HepaRGshPML and HepaRG cells.   Cells were plated in 24-well plates and 
infected with 10-fold serial dilutions as indicated, of the respective Wt (KOS), ICP0 
null (7134) and ICP0 truncation mutant viruses. 3 dpi cells were fixed and stained 
by Immunohistochemistry with a polyclonal antibody against HSV-1. Individual 
viral plaques are shown in red. 
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Figure 3-8. Plaque reduction assays of KOS, 7134 and ICP0 truncation 
mutants in HepaRGshPML vs HepaRG cells in the presence and absence of 
IFN-β. HepaRGshPML and HepaRG cells were mock or pre-treated or not with 
IFN-β (1000 U/mL) and infected 15 post-treatment with serial dilutions of KOS, 
7134 or ICP0 truncation mutants. 3 dpi cells were fixed and stained by 
Immunohistochemistry with a polyclonal antibody against HSV-1.   Titers were 
determined as PFU/ml for all viruses.  The ratio –IFN/+IFN is the viral titer for 
a virus in the absence divided by its titer in the presence of IFN-β. n= 3 
experiments.  Error bars represent the standard errors of the means. 
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As shown in Figure. 3-8, the lack of PML in HepaRG cells modestly 
compensated (3-7-fold) for the plating efficiencies of n212, n428, n525, and 
7134, as indicated by the decrease in the plating efficiency ratio of these 
viruses.  Thus, our data indicate that PML only contributes in a limited 
fashion, at best, to the restriction of IFN-β on HSV-1 growth mediated for the 
ICP0 null and select ICP0 mutant forms we tested.  In addition, the results do 
not precisely correlate with our ICP0 mutant and PML degradation and 
dissociation data in Chapter 2, suggesting that these two functions of ICP0 
(resistance to IFN and PML degradation) are not completely coupled to one 
another. 
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3.4. DISCUSSION 
 
 
HSV-1 establishes a life-long infection in the host, which means that the 
ability of the virus to evade the immune system is crucial for its survival.  
Similar to other viruses, HSV-1 expresses viral gene products that counteract 
host defense mechanisms.   The IE protein, ICP0, is a pivotal player in allowing 
HSV-1 to overcome host antiviral immunity, one part of this immunity being 
the type I IFN response.   As previously mentioned ICP0 null viruses have been 
shown to be hypersensitive to IFNs [78,79].   ICP0 is able to alter the activation 
of the IFN regulatory factor 3 (IRF3) [126,141,142], which participates in 
activating the transcription of IFN-, although the mechanism of how ICP0 
inhibits IRF3 activation is not completely understood.  
 
Many functional regions have been characterized within ICP0, including a 
RING domain, transactivation domains, NLS, domains related to localization 
to ND10s (Figure 3-1).   Nothing is known about what domains in ICP0 are 
involved in its ability to thwart the type 1 IFN response for the benefit of HSV-
1 replication.    To begin to understand how ICP0 impairs the IFN response, 
we performed structure-function analyses using a series of viruses containing 
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progressive C-terminal truncations of ICP0 with the goal to identify at least 
one domain being important for this function.  
  
Monitoring viral fitness by plaque reduction assays in the presence of IFN-β, 
we observed that there was a graduation in the ability of these mutants to 
efficiently replicate, which was inversely proportional to the size of ICP0 
expressed (Figures 3-2 through 3-5).  Specifically, studies show that 7134 and 
the two smallest N-terminus truncation mutants (n212 and n312) were unable 
to produce detectable plaques in HEL cells stimulated with IFN-β and the 
degree of IFN- inhibition was not as severe for n389-n720.  The plaquing 
deficiencies for the initial set of ICP0 mutants we tested were negated on the 
ICP0 complementing (L7) cells, indicating that the phenotypes we observed 
were a result of altering ICP0 function.   Our viral yield assays essentially 
mirrored the plaque reduction assay (Fig. 3-6) and we determined that PML 
only plays a minor in the sensitivity of ICP0 mutants to IFN-.   These data 
highlight that the region up to amino acids 388 as being critical for HSV-1 to 
efficiently replicate in the presence of IFN-, with the residues from 212 to 388 
playing a relevant role in this phenotype.   
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4. CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
 
 
 
HSV-1 is a pathogen that has infected humans for millions of years.   Co-
evolution between host and virus over the centuries has resulted in a pathogen 
that is able to establish a persistent infection for the lifetime of a host.   As 
part of this evolution, the host has developed several antiviral immune 
mechanisms to control viral replication and spread.   These mechanisms 
include intrinsic defenses (see Figure 4-1), such an ND10 and the cellular 
protein, PML, which are cellular factors that are always present and ready to 
repress viral transcription or replication [65].    Another arm of the antiviral 
resistance is the innate immunity (Figure 4-1), where particular molecules or 
patterns associated with viral replication activate a gene cascade that express 
effector proteins [66].   This activation in host gene expression leads to the 
synthesis of type I IFNs, which present a major defense mechanism against 
viruses’ growth [73-75]. 
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Figure 4-1. The HSV-1 ICP0 E3 ubiquitin ligase activity counteracts 
components of host intrinsic and innate immunity. ICP0 achieves this goal 
of counteracting host defenses, by targeting specific cellular proteins for 
degradation or dissociation.  Many ICP0 targets are multi-functional and 
participate in both intrinsic and innate antiviral responses and affect several 
processes, which includes (1) Viral transcription: PML, Sp100, and SUMO; (2) 
Viral genome silencing: IFI16; (3) Inflammatory mechanisms and NF-κB 
regulation: IFI16, MyD88, Mal, NF-kB, and IkB; (4) Viral replication: PARG; (5) 
DNA damage response: RNF168, RNF8, and DNA-PKcs; and (6) ICP0 
destabilization, TLR signaling, Chromatinization, NF-kB signaling: USP7 
(adapted from Cells. 2014 May 20;3(2):438-54}.  
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HSV-1 in turn has acquired counter-defenses to ensure its propagation in the 
human population.  One key component of these defenses is the multi-
functional viral protein, ICP0.   ICP0 possesses E3 Ub ligase activity, through 
which directs the proteasomal-dependent degradation (directly or indirectly) 
of several viral inhibitory function of the host (summarized in Figure 4-1).   
ICP0 disrupt ND10 structures by directing the degradation of PML, the main 
organizer of ND10.  ICP0 has also been shown to impair a pre-existing type 1 
IFN response.   The exact molecular mechanisms of how ICP0 inactivates PML 
and an established type 1 IFN response are still unclear.   The theme of this 
dissertation is to begin to understand how HSV-1 through ICP0 counteracts 
or manipulates intrinsic (PML/ND10) and innate (IFN) defenses.   While select 
functional domains in ICP0 have been known to play a role in these counter-
measures, I hypothesized that other regions in ICP0 contribute to its 
inactivation of PML/Sp100 and the type 1 IFN, IFN-β.   My approach to address 
this overall hypothesis was to do structure-function analyses using a series of 
progressively shorter ICP0 C-terminal truncation mutants (Figures 2-1 and 3-
1) [91,143].  
 
ICP0 potentially exerts these functions within the defined regions of interest, 
with one or more enzymes or proteins that mediate the degradation or 
dispersal of ND10 components (Figure 4-2 a. and b.).   ICP0 motifs contained 
in the broad region (residues 212-427) of ICP0 are phosphorylated regions I 
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and II, and a SIM (Figures 2-1 and 3-1), and each motif has been reported to 
play a role in ICP0’s ability to promote PML and/or Sp100 dissociation from 
ND10s [44,129,130].   Thus, one plausible hypothesis is that these post-
translational modifications or SIM aid in ICP0’s ability to bind to one or more 
cellular adaptor/effectors (Figure 4-2a.).   These interactions promotes the 
degradation and dissociation of SUMOylated-PML and the dissociation of 
Sp100 from ND10, tagging them for proteasomal degradation.    One exception 
is the major isoform of PML, PML I, which has been shown to interact with 
ICP0 in co-immunoprecipitation assays and yeast two-hybrid assays [45].    
ICP0 can mediate the degradation of a non-SUMOylated form of PML I.   These 
data suggest that ICP0 can directly interact with and ubiquitinate PML I, 
providing a potential mechanism in which the portions of the N-terminus of 
ICP0 interacts with PML I in a SUMO-independent manner. 
   
In the case of Sp100 a different domain (residues 1 to 427) within ICP0 seems 
to be necessary for ICP0’s ability to dissociate this ND10 component for the 
complex versus PML dissociation and degradation, suggesting that ICP0 likely 
uses additional mechanisms to alterSp100 localization (Figure 4-2b.).  
      
In Chapter 3, we discovered that the first 388 N-terminal amino acids of ICP0 
are required for HSV-1 effectively resist the antiviral effects of IFN-β, with 
residues spanning from 212-388 important for this function of ICP0 (see 
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Figure 4-2).   As the mutant forms of ICP0, n212 and n312, were expressed at 
very low levels in the presence of IFN-β (data not shown), it is plausible that 
the depletion of these proteins adversely impacts viral replication, similar to 
an ICP0 null mutant.   For these two mutants, we propose that these mutant 
forms of ICP0 may be unable to impair the IFN response because they are not 
capable of activating transcription from the ICP0 promoter, as well as other 
HSV-1 promoters.   In addition, it has been previously shown that Wt HSV-1 
replication in the presence of IFN-β can reduce viral replication, which 
correlates with a reduction in viral DNA replication [144].  Consequently, we 
hypothesize that the residues from 1 to 388 of ICP0 promote DNA synthesis 
or another step late in the viral life cycle by disabling IFN effectors (through 
their degradation or re-localization), leading to the robust production of 
infectious viral progeny (Fig. 4-2c.).    
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Figure 4-2. Model summarizing newly defined functional domains of 
ICP0.   Schematic of ICP0 with selected domains and their amino acid 
residue boundaries, are shown related to their function: orange (aa 1-311), 
PML degradation and dispersion from ND10; pink (aa 1-427) dispersion of 
Sp100 from ND10; and purple (aa 1-388) impairment of the IFN-β 
response.  a., b., and c. are proposed mechanisms of how ICP0 counteracts 
these cellular defenses.  
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Given that I have defined regions in HSV-1 ICP0 that affect two components 
(PML/ND10 and IFN) of cellular defenses, are similar functions or regions 
conserved in other ICP0 homologs?  It has been noted that varicella-zoster 
virus (VZV) ICP0 homolog, ORF61 protein, can complement the replication of 
an HSV-1 ICP0 null mutant [145,146].   Unlike ICP0, ORF61 protein was not 
able to promote the degradation of PML and only moderately affected Sp100 
protein levels [146].  Another comparative study examined the functions of 
ICP0 homologs from BHV-1 (bovine herpes virus type 1), EHV-1 (equine herpes 
virus type 1), PRV (pseudorabies virus), and VZV (varicella-zoster virus).   
These homologs possessed transactivation and in vitro ubiquitination 
activities of ICP0 and could complement and reactivate from quiescent 
infection an ICP0 null mutant [147] for the first three viruses.   However, these 
ICP0 orthologs differentially affected ND10-associated proteins and did not 
appear to interfere with type 1 IFN signaling pathways [147].   Lastly, outside 
of the RING finger domain, there is low level amino acid sequence homology 
between these viral orthologs and ICP0 [123].   Collectively, these data strongly 
suggest the regions we identified in HSV-1 ICP0 that modulate host defenses 
are not conserved among ICP0 homologs, indicating that these other 
herpesviruses have likely evolve diverse mechanisms to counteract similar 
host defenses.  
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As we have examined the interactions between ICP0 and PML/ND10 and ICP0 
and IFN-in this dissertation, the role(s) these cellular factors play in the 
establishment of, or reactivation from, latency have not been extensively 
studied.  PML is known to be expressed in neurons, and it has been shown 
that can form a structure surrounding viral genomes [148].   During latency 
HSV-1 genomes remain chromatinized in the neuronal nucleus as episomes, 
and no infectious virus is detected.  Recent work has suggested that ND10s 
are responsible, together with centromeres, of associating with HSV-1 
genomes, which alters their location and correlates with its silenced 
transcriptional status, and negatively regulates expression of the LATs [148].   
ICP0’s impaired ability to disrupt ND10s and centromeres in one differentiated 
neuronal cell line correlated well with diminished levels of gene expression and 
replication [149].  From these studies, we can hypothesize that ICP0’s ability 
to disrupt ND10s enhances HSV-1 reactivation in neurons, assuming ND10s 
repress lytic gene expression.  
 
Previous studies have implicated type 1 signaling as a relevant defense 
mechanism in neuronal cells from the trigeminal ganglia [150].  ICP0 mutants 
showed to be severely impaired to replicate and establish latency or reactivate 
in animal models, implying a role for ICP0 in these functions [151].  
Additionally, it was shown that suppression of ICP0 expression correlated with 
entry into a quiescent state, despite the fact that other IE proteins were still 
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being made within the cell, supporting a link between ICP0 and quiescence 
[152].   Since ICP0 null mutants are hypersensitive to IFNs [78], the 
relationship HSV-1 and IFNs has been investigated to determine the role of 
the IFN response in latency.   It was noted that certain IFN studies were 
performed in cells that were non-fully differentiated, whereas a new report 
examined the effects of IFN- in neurons derived from adult mice [153].  Data 
from this publication suggest that activation of type 1 IFN signaling alone is 
not sufficient to restrict Wt HSV-1 replication in adult neurons, and that this 
is counteracted at least by the viral factor ICP34.5.   A study by Halford and 
co-workers determined that the ICP0 truncation mutant, n212, was able to 
infect severely immunodeficient mice and establish an efficient latent infection 
[154], suggesting that type 1 IFN signaling plays an important role in the 
establishment of latency.  Consequently, the role of type 1 IFNs in HSV-1 
latency and/or reactivation remains to be resolved.   The characterization of 
ICP0 mutants used in our study as it relates to IFN- signaling in cell culture 
and in vivo will likely shed light on whether ICP0 inactivates the type I IFNs in 
neurons or vice versa or whether ICP0 and type I IFNs have independent 
functions from one another to establish a latent infection or reactivate from 
latency.  
 
In Figure 4-1 several known targets of ICP0’s E3 ubiquitin ligase activity are 
summarized, giving one idea of the breath of how ICP0 counteracts host 
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defenses.  Known targets of ICP0 ubiquitin-proteasomal degradation, directly 
or indirectly, include: PML [39-46]; Sp100 [39,40,46,47], CENP-A, -B, -C [48-
51], DNA-PKcs [47,52,53], RNF-8 and RNF-168 [53], CD83 [54], USP7[55,56], 
IκBα [57], p53 [58], IFI16 [59,60] and E2FBP1 [61], in addition to certain 
SUMOylated targets  [62].   However, ubiquitination of cellular repressors of 
HSV-1 replication by ICP0 may not be exclusively linked to proteolysis.   It is 
well established that E3 Ub ligases can facilitate the ubiquitination of cellular 
targets by conjugation of mono-, multi-, and poly-Ub chains.  These 
conjugations can affect a target protein’s function, localization, and/or 
stability [37].   To the best of our knowledge, the possibility that ICP0’s exploits 
other forms of ubiquitination to control the function of cellular factors is just 
beginning to be explored [64].   Thus, it is logical that a protein as pivotal as 
ICP0 in the HSV-1 life cycle would utilize non-proteosomal ubiquitination of 
cellular factors to inactivate their antiviral functions.   
 
In conclusion, ICP0 is a fascinating multi-functional protein. This IE viral 
protein will provide new insights of antiviral defenses as we begin to 
understand details on the mechanisms of how HSV-1 utilizes ICP0 to evade 
the host immunity.   
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